Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Bought by Deutsche Bank AG

Deutsche Bank AG raised its stake in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 77.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 171,766 shares of the biopharmaceutical company's stock after purchasing an additional 75,212 shares during the period. Deutsche Bank AG owned 0.09% of Arbutus Biopharma worth $562,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in shares of Arbutus Biopharma by 5.7% during the fourth quarter. Invesco Ltd. now owns 69,831 shares of the biopharmaceutical company's stock worth $228,000 after acquiring an additional 3,780 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Arbutus Biopharma by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 40,179 shares of the biopharmaceutical company's stock worth $131,000 after acquiring an additional 3,870 shares during the last quarter. Teacher Retirement System of Texas grew its stake in shares of Arbutus Biopharma by 18.7% during the fourth quarter. Teacher Retirement System of Texas now owns 42,144 shares of the biopharmaceutical company's stock worth $138,000 after acquiring an additional 6,644 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Arbutus Biopharma by 18.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 56,452 shares of the biopharmaceutical company's stock worth $185,000 after acquiring an additional 8,648 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Arbutus Biopharma by 11.0% during the third quarter. JPMorgan Chase & Co. now owns 89,586 shares of the biopharmaceutical company's stock worth $345,000 after acquiring an additional 8,859 shares during the last quarter. Hedge funds and other institutional investors own 43.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Arbutus Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, March 29th. Chardan Capital restated a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $5.50.

Arbutus Biopharma Stock Performance

NASDAQ ABUS remained flat at $3.36 during trading hours on Monday. The company had a trading volume of 551,419 shares, compared to its average volume of 990,112. The company's 50-day moving average is $3.27 and its two-hundred day moving average is $3.33. The stock has a market cap of $643.53 million, a PE ratio of -7.81 and a beta of 1.50. Arbutus Biopharma Co. has a 52-week low of $2.71 and a 52-week high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.04). The firm had revenue of $1.76 million during the quarter, compared to analysts' expectations of $2.54 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. On average, equities analysts forecast that Arbutus Biopharma Co. will post -0.39 earnings per share for the current fiscal year.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.